US49705R1059 - Common Stock
KINNATE BIOPHARMA INC
NASDAQ:KNTE (9/27/2023, 7:00:02 PM)
1.47
+0.09 (+6.52%)
Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. The company is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. The company is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
KINNATE BIOPHARMA INC
11975 El Camino Real, Ste 101, Suite 101
San Diego CALIFORNIA 92130
P: 18582994699.0
CEO: Nima Farzan
Employees: 84
Website: https://www.kinnate.com/
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning!
Kinnate Biopharma (KNTE) said late Monday that it was slashing its workforce by 70% as part of a reprioritization of its drug development programs. Read more here.
Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to...
Here you can normally see the latest stock twits on KNTE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: